Vaaji Smart Patch Study Achieves Perfect Accuracy in Medication Monitoring

The successful completion of a pilot study conducted by Vaaji in collaboration with the Penn Artificial Intelligence and Technology Collaboratory at the University of Pennsylvania has demonstrated 100% technical accuracy in monitoring patch status. These results validate Vaaji's proprietary smart patch system as a robust tool with the potential to significantly improve safety in transdermal drug delivery. Transdermal patches are a vital delivery mechanism for medications treating Alzheimer's, Parkinson's, and pain management, but patients or caregivers may accidentally apply new patches without removing old ones or forget applications entirely, leading to ineffective treatment or potentially life-threatening overdoses.

Vaaji is developing a solution to transform standard passive patches into smart therapeutics by leveraging advanced Internet of Things sensors and Artificial Intelligence to provide real-time visibility into medication adherence. The proof-of-concept study enrolled 51 healthy volunteers using placebo patches to evaluate the system's detection capabilities against manual oversight. The results confirmed the platform's technical reliability with 100% agreement between Vaaji's remote monitoring data and site investigator records, matching the gold standard of direct human supervision. The system successfully identified simulated patch stacking in real-time, validating the core technology required to prevent overdose events in future clinical applications.

Patrick Mercier, Professor of Electrical and Computer Engineering at UCSD and Chief Technical Advisor at Vaaji, stated that this study provides the first real-world evidence that their smart patch platform can deliver perfect accuracy in detecting patch application errors. William Z. Potter, MD, PhD, co-Principal Investigator and Chief Scientific Advisor at Vaaji, noted that the 100% agreement between remote monitoring and site investigator records is a landmark result for this early-stage development. Sandeep Patil, MD, PhD, Co-founder of Vaaji, emphasized that with the aging population growing rapidly, the need for technologies that enable safe, independent living is more urgent than ever.

The exploratory study was part of the AI/Tech + Aging Collective funded by the National Institute on Aging. The data from this pilot study will inform Vaaji's clinical and regulatory strategy as the company advances toward broader clinical trials involving active therapeutics. The company aims to establish its smart monitoring platform as a new safety standard for high-risk transdermal medications. For more information on Vaaji's patient-centric platform, visit https://www.vaaji.io. The project described is supported by the National Institute on Aging of the National Institutes of Health under Award Number 1-P30-AG-073105-01.